Background: NPC-1C (NEO-101; Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancers. This antibody was selected from a panel of hybridomas generated from mice immunized with semi-purified membrane-associated proteins derived from biologically screened, pooled human allogeneic colon cancer tissues. The NPC-1C target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumors with only occasional minimal cross-reactivity to certain normal GI tract tissues.
Background

History of NPC-1C Development
• NPC-1C was developed from a previous cancer vaccine derived from antigens isolated from pooled tumor extracts obtained from surgical samples from patients with colorectal cancer.
• Arlen M, et al. Cancer 56(3):480-9, 1985) A • Killing activity via ADCC ranging from 25-65% tumor cell lysis in 4 hour Cr release assay.
Pre-Clinical In Vivo Data
• Anti-tumor activity was demonstrated with NPC-1C in mice bearing established human pancreatic cell lines.
• PK testing in animals supports dosing every two weeks.
• Biodistribution studies indicate that NPC-1C can traffic to the tumor site following intravenous administration and potentially effect an anti-tumor effect.
• Animal toxicity studies did not identify toxicities associated with the administration of NPC-1C. 
